Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review

BACKGROUND: Darunavir is a second-generation protease-inhibitor used with ritonavir (DRV/r) and two nucleoside reverse-transcriptase inhibitors as an option in first-line antiretroviral treatment (ART). METHODS: We systematically reviewed randomized controlled trials (RCTs) of DRV/r versus other reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Balayan, Tatevik, Horvath, Hacsi, Rutherford, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634582/
https://www.ncbi.nlm.nih.gov/pubmed/29082041
http://dx.doi.org/10.1155/2017/2345617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634582/
https://www.ncbi.nlm.nih.gov/pubmed/29082041
http://dx.doi.org/10.1155/2017/2345617

Ejemplares similares